Sikander Ailawadhi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6404356/publications.pdf

Version: 2024-02-01

200	2,584	236925	254184
papers	citations	25 h-index	43 g-index

204	204	204	3726
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
2	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
3	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
4	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
5	Outcome disparities in multiple myeloma: a <scp>SEER</scp>â€based comparative analysis of ethnic subgroups. British Journal of Haematology, 2012, 158, 91-98.	2.5	97
6	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
7	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
8	Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Advances, 2019, 3, 2986-2994.	5.2	70
9	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer Journal, 2018, 8, 67.	6.2	66
10	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 372-380.	0.4	66
11	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp>â€medicare analysis. Cancer Medicine, 2017, 6, 2876-2885.	2.8	63
12	Targeted inhibition of the deubiquitinating enzymes, <scp>USP</scp>14 and <scp>UCHL</scp>5, induces proteotoxic stress and apoptosis in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia tumour cells. British Journal of Haematology, 2015, 169, 377-390.	2.5	55
13	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CDâ€“56-positive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 29-34.	0.4	53
14	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	1.4	51
15	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology,the, 2018, 5, e170-e180.	4.6	44
16	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal, 2019, 9, 75.	6.2	43
17	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer, 2018, 124, 1710-1721.	4.1	40
18	Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsedâ€“refractory Multiple Myeloma in the United States. Clinical Therapeutics, 2017, 39, 1986-2005.e5.	2.5	39

#	Article	IF	Citations
19	Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist, 2018, 23, 1076-1078.	3.7	37
20	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 17.	6.2	35
21	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 2020, 13, 421-433.	2.2	34
22	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
23	Second primary acute lymphoblastic leukemia in adults: a <scp>SEER</scp> analysis of incidence and outcomes. Cancer Medicine, 2018, 7, 499-507.	2.8	29
24	The Determinants of Palliative Care Use in Patients With Colorectal Cancer: A National Study. American Journal of Hospice and Palliative Medicine, 2018, 35, 1295-1303.	1.4	29
25	Outcome Disparities among Ethnic Subgroups of WaldenstrÃ¶m's Macroglobulinemia: A Population-Based Study. Oncology, 2014, 86, 253-262.	1.9	27
26	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 578-585.	0.4	27
27	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Advances, 2020, 4, 2143-2157.	5.2	27
28	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
29	Survival trends among nonâ€smallâ€cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Medicine, 2018, 7, 4932-4942.	2.8	25
30	Palliative Care Use Among Patients With Solid Cancer Tumors. Journal of Palliative Care, 2018, 33, 149-158.	1.0	25
31	Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2019, 25, 3974-3985.	7.0	25
32	Many Shades of Disparities in Myeloma Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 519-529.	3.8	24
33	Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM). Blood, 2012, 120, 728-728.	1.4	23
34	Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. Current Hematologic Malignancy Reports, 2017, 12, 309-316.	2.3	22
35	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia and Lymphoma, 2020, 61, 309-317.	1.3	22
36	Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2032276.	5.9	22

#	Article	IF	Citations
37	Development and characterization of a novel human WaldenstrÃ¶m macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute â€“ WaldenstrÃ¶m Macroglobulinemia 1. Leukemia and Lymphoma, 2013, 54, 387-396.	1.3	21
38	Impact of access to <scp>NCI</scp>â€•and <scp>NCCN</scp>â€‘designated cancer centers on outcomes for multiple myeloma patients: A <scp>SEER</scp> registry analysis. Cancer, 2016, 122, 618-625.	4.1	21
39	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 9-22.	0.4	21
40	Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1174-1182.	1.3	19
41	Commentary: Race and Ethnicity in Biomedical Research â€“ Classifications, Challenges, and Future Directions. Ethnicity and Disease, 2018, 28, 561-564.	2.3	19
42	Influence of Sociodemographic Factors on Treatment Decisions in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e115-e129.	2.6	19
43	Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e449-e455.	0.4	19
44	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
45	Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Review of Hematology, 2017, 10, 1107-1119.	2.2	18
46	Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Advances, 2018, 2, 1120-1128.	5.2	18
47	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. Cancer, 2020, 126, 4332-4340.	4.1	18
48	Immunophenotyping of WaldenstrÃ¶ms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications. PLoS ONE, 2015, 10, e0122338.	2.5	17
49	Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Annals of Hematology, 2018, 97, 519-528.	1.8	17
50	Targeting CD38 with daratumumab is lethal to WaldenstrÃ¶m macroglobulinaemia cells. British Journal of Haematology, 2018, 183, 196-211.	2.5	16
51	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 272-276.	0.4	16
52	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood, 2016, 128, 792-792.	1.4	16
53	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
54	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematology,the, 2021, 8, e794-e807.	4.6	15

#	Article	IF	Citations
55	Connect MM Registry as a national reference for United States multiple myeloma patients. Cancer Medicine, 2020, 9, 35-42.	2.8	14
56	Impact of belantamab mafodotinâ€induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology, 2022, 199, 95-99.	2.5	14
57	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clinical Cancer Research, 2020, 26, 3969-3978.	7.0	13
58	Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer Journal, 2022, 12, 46.	6.2	13
59	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
60	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	12
61	Nuances in the Management of Older People With Multiple Myeloma. Current Hematologic Malignancy Reports, 2016, 11, 241-251.	2.3	11
62	Extramedullary Solitary Plasmacytoma: Demonstrating the Role of 18F-FDG PET Imaging. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XD01-XD03.	0.8	11
63	Survival trends in glioblastoma and association with treating facility volume. Journal of Clinical Neuroscience, 2019, 68, 271-274.	1.5	11
64	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. JCO Oncology Practice, 2020, 16, e341-e349.	2.9	11
65	Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers, 2021, 13, 5770.	3.7	11
66	Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 576-589.e1.	0.4	10
67	Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 619-623.	0.4	10
68	Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clinical Therapeutics, 2019, 41, 477-493.e7.	2.5	10
69	Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination. Blood, 2010, 116, 1934-1934.	1.4	10
70	Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 216-228.	1.7	9
71	Cardiac Myeloid Sarcoma: Review of Literature. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, XE01-XE04.	0.8	9
72	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. Journal of Gastrointestinal Oncology, 2018, 9, 1063-1073.	1.4	9

#	Article	IF	Citations
73	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2016, 128, 1891-1891.	1.4	9
74	Updates in prognostication and treatment of WaldenstrÃ¶mâ€™s macroglobulinemia. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 179-188.	0.9	8
75	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncology Practice, 2020, 16, e1169-e1180.	2.9	8
76	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	1.4	8
77	Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome. Blood, 2018, 132, 1911-1911.	1.4	8
78	A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. Blood, 2021, 138, 1675-1675.	1.4	8
79	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	6
80	Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Therapeutic Advances in Hematology, 2017, 8, 3-12.	2.5	5
81	Predictors of palliative treatment in stage IV colorectal cancer. American Journal of Surgery, 2019, 218, 514-520.	1.8	5
82	Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Reports in Hematology, 2020, 2020, 1-6.	0.4	5
83	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 355-360.	0.4	5
84	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncology Practice, 2021, 17, e1382-e1393.	2.9	5
85	The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant WaldenstrÃ¶ms Macroglobulinemia. Blood, 2014, 124, 1689-1689.	1.4	5
86	Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells. Blood, 2016, 128, 3018-3018.	1.4	5
87	Deep Sequencing Reveals Lack of a Clonal Relationship Between a Metachronous Classical Hodgkin and Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e87-e93.	0.4	4
88	Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Annals of Hematology, 2015, 94, 1603-1604.	1.8	4
89	Preclinical models of WaldenstrÃ¶m's macroglobulinemia and drug resistance. Best Practice and Research in Clinical Haematology, 2016, 29, 169-178.	1.7	4
90	Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant. Annals of Hematology, 2017, 96, 2125-2126.	1.8	4

#	Article	IF	Citations
91	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. British Journal of Haematology, 2019, 185, 347-350.	2.5	4
92	Effect of initial treatment on healthâ€related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect^{Â®} MM Registry. British Journal of Haematology, 2021, 193, 93-100.	2.5	4
93	Challenges of Cellular Therapy During the COVID-19 Pandemic. Advances in Experimental Medicine and Biology, 2021, 1318, 657-672.	1.6	4
94	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. Journal of Oncology Pharmacy Practice, 2022, 28, 1130-1139.	0.9	4
95	Mental Health and Chemical Dependency Services at US Cancer Centers. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 829-838.	4.9	4
96	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Annals of Hematology, 2021, 100, 735-741.	1.8	4
97	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
98	Ethnic Disparities in Chronic Lymphocytic Leukemia Survival: A SEER Database Review. Blood, 2012, 120, 757-757.	1.4	4
99	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. Blood, 2015, 126, 703-703.	1.4	4
100	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. Blood, 2017, 130, 864-864.	1.4	4
101	Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematological Oncology, 2022, 40, 695-703.	1.7	4
102	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
103	Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.). Blood, 2019, 134, 3164-3164.	1.4	3
104	Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 144-144.	1.4	3
105	Imatinib Meslylate Plasma Levels Predict Compliance in Patients with Chronic Myelogenous Leukemia.. Blood, 2009, 114, 4274-4274.	1.4	3
106	Acquired in Vitro Resistance to Ibrutinib Is Associated with Transcriptional Re-Programming and Sustained Survival Signaling in WaldenstrÃ¶ms Macroglobulinemia and Mantle Cell Lymphoma, Independent of BTK Cys481 Mutation. Blood, 2014, 124, 2250-2250.	1.4	3
107	Therapeutic Sensitivity of CD20- WaldenstrÃ¶ms Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events. Blood, 2014, 124, 3115-3115.	1.4	3
108	Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL). Blood, 2015, 126, 5299-5299.	1.4	3

#	Article	IF	Citations
109	Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM). Blood, 2016, 128, 3544-3544.	1.4	3
110	CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial. Blood, 2021, 138, 1652-1652.	1.4	3
111	Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple Myeloma. Anticancer Research, 2020, 40, 5727-5734.	1.1	3
112	Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anti-Cancer Drugs, 2019, 30, 859-865.	1.4	2
113	Ixazomib and lenalidomide maintenance therapy in multiple myeloma. Annals of Hematology, 2021, 100, 851-853.	1.8	2
114	A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2022, 30, 227-235.	2.2	2
115	Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers. Cancer, 2021, 127, 1770-1778.	4.1	2
116	Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the ConnectÂ® MM Registry. Blood, 2018, 132, 3232-3232.	1.4	2
117	Disease Knowledge In Chronic Myeloid Leukemia (CML) Patients as a Predictor of Compliance to Treatment.. Blood, 2010, 116, 4481-4481.	1.4	2
118	Secondary Acute Lymphoblastic Leukemia after Primary Solid Organ Malignancy: A SEER Analysis of Incidence and Outcomes. Blood, 2014, 124, 935-935.	1.4	2
119	Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma. Blood, 2015, 126, 1557-1557.	1.4	2
120	Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update. Blood, 2016, 128, 1191-1191.	1.4	2
121	Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials. Blood, 2016, 128, 1192-1192.	1.4	2
122	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
123	Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database. Blood, 2016, 128, 4432-4432.	1.4	2
124	Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma. Blood, 2016, 128, 4480-4480.	1.4	2
125	High-Dose Cyclophosphamide: An Effective Non-Transplant Salvage Option in Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 4947-4947.	1.4	2
126	Ethnic Disparities and Their Association With Outcomes In Chronic Myeloid Leukemia. Blood, 2013, 122, 2917-2917.	1.4	2

#	Article	IF	Citations
127	A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1. Blood, 2013, 122, 3111-3111.	1.4	2
128	Methylation Patterns in WaldenstrÃ¶ms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors. Blood, 2014, 124, 3551-3551.	1.4	2
129	Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation. Blood, 2015, 126, 2754-2754.	1.4	2
130	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
131	Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. Clinical Hematology International, 2020, 2, 117.	1.7	2
132	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
133	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2735-2735.	1.4	2
134	Plamotamab (XmAb^{Â®}13676) for Ibrutinib- refractory CXCR4-mutated extramedullary WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2022, 63, 738-742.	1.3	2
135	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). Blood, 2020, 136, 29-30.	1.4	2
136	Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clinical Case Reports (discontinued), 2021, 9, e05181.	0.5	2
137	Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 773958.	2.8	2
138	Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. Cancer Research, 2022, 82, CT186-CT186.	0.9	2
139	Multiple asymptomatic colon plasmacytomas: a diagnostic and therapeutic dilemma. Annals of Hematology, 2015, 94, 1061-1062.	1.8	1
140	Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Annals of Hematology, 2017, 96, 51-55.	1.8	1
141	Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 711-712.	0.9	1
142	Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia. SAGE Open Medical Case Reports, 2019, 7, 2050313X1882391.	0.3	1
143	Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. Journal of Oncology Pharmacy Practice, 2020, 26, 1070-1079.	0.9	1
144	Impact of Depression and Anxiety on Opioid UseÂin Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics, 2020, 61, 363-370.	2.5	1

#	Article	IF	Citations
145	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. Blood, 2018, 132, 3244-3244.	1.4	1
146	Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US). Blood, 2019, 134, 1827-1827.	1.4	1
147	Explaining the Excess Risk of Multiple Myeloma in African-Americans. Blood, 2012, 120, 4002-4002.	1.4	1
148	Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance. Blood, 2016, 128, 2761-2761.	1.4	1
149	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). Blood, 2016, 128, 3250-3250.	1.4	1
150	Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis. Blood, 2016, 128, 3542-3542.	1.4	1
151	Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM). Blood, 2016, 128, 3582-3582.	1.4	1
152	Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis. Blood, 2016, 128, 3612-3612.	1.4	1
153	Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 4485-4485.	1.4	1
154	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.. Journal of Clinical Oncology, 2018, 36, 8037-8037.	1.6	1
155	Outcome Disparities In Multiple Myeloma: A SEER-Based Comparative Analysis of Hispanic Patients. Blood, 2010, 116, 396-396.	1.4	1
156	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. Blood, 2015, 126, 1839-1839.	1.4	1
157	Secondary Cancers in Hodgkin Lymphoma: A Comprehensive Analysis of Incidence and Trends in Survivors. Blood, 2017, 130, 913-913.	1.4	1
158	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
159	Decreased Physical Activity in Autologous Stem Cell Recipients Leads to Reduced QOL Scores during Hospitalization. Blood, 2018, 132, 5895-5895.	1.4	1
160	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
161	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. Blood, 2018, 132, 5873-5873.	1.4	1
162	Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C). Case Reports in Genetics, 2016, 2016, 1-4.	0.2	0

#	Article	IF	Citations
163	Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. Journal of Oncology Pharmacy Practice, 2022, 28, 425-433.	0.9	0
164	Ethnic Disparities in Multiple Myeloma: A Comparative Analysis of Hispanic Patients.. Blood, 2009, 114, 4875-4875.	1.4	0
165	Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.. Blood, 2009, 114, 4895-4895.	1.4	0
166	Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.. Blood, 2009, 114, 618-618.	1.4	0
167	Combination Therapy with BCNU/Etoposide/Melphalan (BEM) as Conditioning Regimen for Autologous Stem Cell Transplant In Multiple Myeloma.. Blood, 2010, 116, 4587-4587.	1.4	0
168	Trends in Incidence and Survival of Multiple Myeloma with Second Primary Malignancy,. Blood, 2011, 118, 3958-3958.	1.4	0
169	Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis. Blood, 2011, 118, 845-845.	1.4	0
170	Variable Risk of Second Primary Malignancy In Multiple Myeloma Patients of Different Ethnicities. Blood, 2011, 118, 678-678.	1.4	0
171	Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma and the Impact On Survival. Blood, 2012, 120, 601-601.	1.4	0
172	Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans. Blood, 2013, 122, 1872-1872.	1.4	0
173	Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma. Blood, 2013, 122, 5350-5350.	1.4	0
174	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.	1.4	0
175	Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199. Blood, 2015, 126, 4839-4839.	1.4	0
176	Socio-Demographic Parameters Including Race, As Predictors of Depression in Patients with Hematologic Malignancies. Blood, 2015, 126, 4517-4517.	1.4	0
177	Psychiatric Comorbidities Are Associated with Increased Cost of Care and Healthcare Utilization in Multiple Myeloma (MM) Patients. Blood, 2016, 128, 1238-1238.	1.4	0
178	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	1.4	0
179	Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab. Blood, 2016, 128, 5946-5946.	1.4	0
180	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. Blood, 2017, 130, 862-862.	1.4	0

#	Article	IF	Citations
181	Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities. Blood, 2017, 130, 860-860.	1.4	0
182	Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities. Blood, 2018, 132, 4867-4867.	1.4	0
183	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL). Blood, 2018, 132, 4869-4869.	1.4	0
184	Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States. Blood, 2018, 132, 4861-4861.	1.4	0
185	Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo. Blood, 2018, 132, 5558-5558.	1.4	0
186	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	1.4	0
187	Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US). Blood, 2018, 132, 4765-4765.	1.4	0
188	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. Blood, 2018, 132, 4764-4764.	1.4	0
189	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. Blood, 2018, 132, 4852-4852.	1.4	0
190	Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States. Blood, 2018, 132, 4868-4868.	1.4	0
191	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	1.4	0
192	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. Blood, 2019, 134, 5610-5610.	1.4	0
193	ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies. Blood, 2021, 138, 1409-1409.	1.4	0
194	Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience. Blood, 2021, 138, 665-665.	1.4	0
195	REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study. Blood, 2021, 138, 1967-1967.	1.4	0
196	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). Blood, 2021, 138, 2285-2285.	1.4	0
197	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naÃ¯ve) or after Progression on Sequential I and V (Double-Refractory). Blood, 2021, 138, 1560-1560.	1.4	0
198	Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V],) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 72 Td Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US). Blood, 2020, 136, 47-48.	1.4	0

#	Article	IF	Citations
199	Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients. Blood, 2020, 136, 39-40.	1.4	0
200	Myelomatous ascites and pleural effusion in relapsed multiple myeloma. Clinical Case Reports (discontinued), 2022, 10, e05329.	0.5	0